South Korea
· Delayed Price · Currency is KRW SyntekaBio Statistics
Total Valuation
SyntekaBio has a market cap or net worth of KRW 85.29 billion. The enterprise value is 76.23 billion.
| Market Cap | 85.29B |
| Enterprise Value | 76.23B |
Important Dates
The next estimated earnings date is Friday, March 21, 2025.
| Earnings Date | Mar 21, 2025 |
| Ex-Dividend Date | n/a |
Share Statistics
SyntekaBio has 15.26 million shares outstanding. The number of shares has increased by 8.34% in one year.
| Current Share Class | n/a |
| Shares Outstanding | 15.26M |
| Shares Change (YoY) | +8.34% |
| Shares Change (QoQ) | -0.00% |
| Owned by Insiders (%) | 17.29% |
| Owned by Institutions (%) | 1.90% |
| Float | 12.62M |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | n/a |
| PB Ratio | 2.93 |
| P/TBV Ratio | 2.98 |
| P/FCF Ratio | n/a |
| P/OCF Ratio | n/a |
| PEG Ratio | n/a |
Enterprise Valuation
| EV / Earnings | -4.65 |
| EV / Sales | n/a |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | -4.18 |
Financial Position
The company has a current ratio of 1.00, with a Debt / Equity ratio of 0.26.
| Current Ratio | 1.00 |
| Quick Ratio | 0.97 |
| Debt / Equity | 0.26 |
| Debt / EBITDA | n/a |
| Debt / FCF | -0.42 |
| Interest Coverage | -8.07 |
Financial Efficiency
Return on equity (ROE) is -41.96% and return on invested capital (ROIC) is -18.48%.
| Return on Equity (ROE) | -41.96% |
| Return on Assets (ROA) | -13.50% |
| Return on Capital (ROIC) | -18.48% |
| Revenue Per Employee | 1.97M |
| Profits Per Employee | -264.15M |
| Employee Count | 62 |
| Asset Turnover | 0.00 |
| Inventory Turnover | n/a |
Taxes
| Income Tax | n/a |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has decreased by -50.80% in the last 52 weeks.
| Beta (5Y) | n/a |
| 52-Week Price Change | -50.80% |
| 50-Day Moving Average | 5,713.70 |
| 200-Day Moving Average | 7,679.58 |
| Relative Strength Index (RSI) | 46.68 |
| Average Volume (20 Days) | 377,179 |
Short Selling Information
| Short Interest | n/a |
| Short Previous Month | n/a |
| Short % of Shares Out | n/a |
| Short % of Float | n/a |
| Short Ratio (days to cover) | n/a |
Income Statement
In the last 12 months, SyntekaBio had revenue of KRW 122.33 million and -16.38 billion in losses. Loss per share was -1,074.48.
| Revenue | 122.33M |
| Gross Profit | 119.53M |
| Operating Income | -13.49B |
| Pretax Income | -16.38B |
| Net Income | -16.38B |
| EBITDA | -11.22B |
| EBIT | -13.49B |
| Loss Per Share | -1,074.48 |
Balance Sheet
The company has 16.70 billion in cash and 7.63 billion in debt, giving a net cash position of 9.06 billion or 593.95 per share.
| Cash & Cash Equivalents | 16.70B |
| Total Debt | 7.63B |
| Net Cash | 9.06B |
| Net Cash Per Share | 593.95 |
| Equity (Book Value) | 29.08B |
| Book Value Per Share | 1,905.91 |
| Working Capital | -7.67M |
Cash Flow
In the last 12 months, operating cash flow was -9.22 billion and capital expenditures -9.03 billion, giving a free cash flow of -18.25 billion.
| Operating Cash Flow | -9.22B |
| Capital Expenditures | -9.03B |
| Free Cash Flow | -18.25B |
| FCF Per Share | -1,196.27 |
Margins
| Gross Margin | 97.71% |
| Operating Margin | -11,030.76% |
| Pretax Margin | -13,387.52% |
| Profit Margin | n/a |
| EBITDA Margin | n/a |
| EBIT Margin | n/a |
| FCF Margin | n/a |
Dividends & Yields
SyntekaBio does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| Buyback Yield | -8.34% |
| Shareholder Yield | -8.34% |
| Earnings Yield | -19.22% |
| FCF Yield | -21.40% |
Stock Splits
This stock does not have any record of stock splits.
| Last Split Date | n/a |
| Split Type | n/a |
| Split Ratio | n/a |
Scores
SyntekaBio has an Altman Z-Score of 1.62. A Z-score under 3 suggests an increased risk of bankruptcy.
| Altman Z-Score | 1.62 |
| Piotroski F-Score | n/a |